🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. copolymer 1

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  2. coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume

    NovoThirteen

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  3. cpFT

    Pari Pharma GmbH

    Infertility

    phase 3 small molecule active

    1 trial

  4. dabigatran dose 1

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  5. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  6. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  7. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  8. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  9. edoxaban tosylate(DU-176b)

    Daiichi Sankyo

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  10. elafibranor, Elafibranor Placebo

    Ipsen

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  11. elafibranor, Placebo

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  12. elafibranor, Placebo tablet

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  13. elritercept, Placebo to match ker-050 solution for injection

    Takeda

    myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  14. enfortumab vedotin, VINFLUNINE , DOCETAXEL , PACLITAXEL

    Astellas Pharma GmbH

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  15. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  16. fexofenadine HCL (M016455)

    Sanofi Pasteur

    Rhinitis Seasonal

    phase 3 small molecule completed

    1 trial

  17. giroctocogene fitelparvovec

    Pfizer Australia Pty Ltd

    hemophilia A

    phase 3 small molecule active

    1 trial

  18. giroctocogene fitelparvovec, fidanacogene elaparvovec

    Pfizer Australia Pty Ltd

    hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)

    phase 3 small molecule active

    1 trial

  19. granules for suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Ataxia Telangiectasia

    phase 3 small molecule active

    1 trial

  20. hydroxychloroquine (Z0188)

    Sanofi Pasteur

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  21. infigratinib 0.128 mg/kg/day

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  22. innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα

    The George Institute

    Thromboprophylaxis in patients with advanced pancreatic cancer

    phase 3 small molecule active

    1 trial

  23. lactose monohydrate - 100,00 mg/tablet cellulose microcrystalline - 95,60 mg/tablet Croscarmellose sodium - 2,00 mg/tablet Magnesium stearate - 2,40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON, Asmenol, 10 mg, tabletki powlekane

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  24. levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

    Teva Pharma GmbH

    Dysmenorrhea

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources